RevBio to Begin Clinical Trial for Regenerative Biomaterial

A new study from RevBio aims to assess the timeline for its regenerative biomaterial Tetranite to work in cases of dental implants.

RevBio announced that it has received approval from the Italian Ministry of Health and the Ethics committee of the University “G.D Annunzio” of Chieti-Pescara to begin a clinical trial to assess the necessary timeline for the company’s biomaterial Tetranite® to regenerate bone in the mandibular and maxillary arches.

Led by Professor Sergio Caputi, MD, DDS, this study will dive deep on the proven Tetranite from RevBio. It will be researched by a team comprised of experts, including Professor Maurizio Piatelli, MD, DDS, Tonino Traini, DDS, PhD, Bruna Sinjari, DDS, PhD, Gianmaria D’Addazio, DDS, PhD, and Manlio Santilli, DDS, PhD student. This team of dental professionals has been planning this study and are excited to get off the ground, according to Dr Sinjari.

“We are very pleased to see this study come together after much planning during the COVID-19 pandemic,” Dr Sinjari says in a press release from RevBio. “We have assembled a great research team which will be able to assess the unique osteoconductive properties of this biomaterial.”

While Tetranite has already been properly studied on the efficacy of its regenerative properties, this new study will take a closer look at the specific timeline of the osteo-regeneration, according to the press release.